DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Increase in Short Interest

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 222,800 shares, an increase of 14.5% from the December 31st total of 194,600 shares. Based on an average trading volume of 93,700 shares, the short-interest ratio is currently 2.4 days.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ:DMAC traded down $0.09 during midday trading on Friday, reaching $5.76. 53,263 shares of the company’s stock traded hands, compared to its average volume of 77,588. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $6.41. The stock has a 50 day moving average of $5.48 and a 200 day moving average of $4.53. The company has a market cap of $246.30 million, a price-to-earnings ratio of -10.29 and a beta of 1.46.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of DiaMedica Therapeutics in a research note on Friday, November 15th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of DiaMedica Therapeutics in the third quarter worth about $40,000. Blue Trust Inc. purchased a new stake in shares of DiaMedica Therapeutics during the third quarter worth about $185,000. Finally, Geode Capital Management LLC grew its position in shares of DiaMedica Therapeutics by 29.6% during the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after purchasing an additional 70,070 shares in the last quarter. Institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.